We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+32.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$183M
Cap. Flow
-$318M
Cap. Flow %
-35.32%
Top 10 Hldgs %
45.07%
Holding
107
New
16
Increased
16
Reduced
34
Closed
34

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$25.1M
2
PEN icon
Penumbra
PEN
+$17.6M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$16.9M
4
GSK icon
GSK
GSK
+$12M
5
NUVL
Nuvalent
NUVL
+$10.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$26M
2
ACLX
Arcellx
ACLX
+$21.9M
3
PODD icon
Insulet
PODD
+$20.4M
4
EOLS icon
Evolus
EOLS
+$19M
5
CRL icon
Charles River Laboratories
CRL
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
76
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-3,900
Closed -$691K
AVDL
77
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-104,000
Closed -$1.07M
AXSM icon
78
Axsome Therapeutics
AXSM
$10.9B
– –
-237,500
Closed -$16.6M
BHC icon
79
Bausch Health
BHC
$2.34B
– –
-1,408,801
Closed -$11.6M
BHVN icon
80
Biohaven
BHVN
$2.21B
– –
-113,800
Closed -$2.96M
BLFS icon
81
BioLife Solutions
BLFS
$1.69B
– –
-439,000
Closed -$6.06M
BNTX icon
82
BioNTech
BNTX
$23.5B
– –
-98,000
Closed -$10.6M
CRL icon
83
Charles River Laboratories
CRL
$12.8B
– –
-96,064
Closed -$18.8M
DCTH icon
84
Delcath Systems
DCTH
$522M
– –
-144,958
Closed -$587K
DSGN icon
85
Design Therapeutics
DSGN
$876M
– –
-1,025,000
Closed -$2.42M
EOLS icon
86
Evolus
EOLS
$501M
– –
-2,078,000
Closed -$19M
ETNB
87
DELISTED
89bio
ETNB
– –
-346,033
Closed -$5.34M
EXAS
88
DELISTED
Exact Sciences
EXAS
– –
-102,196
Closed -$6.97M
DMRA
89
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
– –
-35,906
Closed -$646K
INSP icon
90
Inspire Medical Systems
INSP
$1.74B
– –
-35,600
Closed -$7.06M
KNSA icon
91
Kiniksa Pharmaceuticals
KNSA
$5.93B
– –
-157,349
Closed -$2.73M
KROS icon
92
Keros Therapeutics
KROS
$221M
– –
-12,700
Closed -$405K
LYRA
93
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-11,848
Closed -$2.32M
MCRB icon
94
Seres Therapeutics
MCRB
$48.4M
– –
-91,049
Closed -$4.33M
MIRM icon
95
Mirum Pharmaceuticals
MIRM
$6.14B
– –
-103,000
Closed -$3.25M
NTRA icon
96
Natera
NTRA
$46.1B
– –
-61,377
Closed -$2.72M
PODD icon
97
Insulet
PODD
$9.79B
– –
-127,680
Closed -$20.4M
PRAX icon
98
Praxis Precision Medicines
PRAX
$10.1B
– –
-76,667
Closed -$1.97M
SLNO
99
DELISTED
Soleno Therapeutics
SLNO
– –
-325,000
Closed -$9.59M
SPRY icon
100
ARS Pharmaceuticals
SPRY
$612M
– –
-150,000
Closed -$567K
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Soleus Capital Management held 107 positions worth $901M, down 17% from $1.08B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management withdrew a net $318M in Q4 2023, closing 34 positions and reducing 34 holdings. Its most notable exit was Insulet, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $27.5M.

  • Soleus Capital Management's largest Q4 2023 buy was HCA Healthcare: 101,500 shares worth $27.5M.
  • Soleus Capital Management added most to GSK in Q4 2023, an estimated $12M increase.
  • Soleus Capital Management's biggest Q4 2023 reduction was TG Therapeutics, cutting an estimated $26M.
  • Soleus Capital Management fully exited Insulet in Q4 2023, selling an estimated $20.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $901M portfolio in Q4 2023.
  • Soleus Capital Management opened 16 new positions and closed 34 in Q4 2023.
  • Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $901M.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.